Clearly understanding the basics to pharmacokinetics: Extracts from The Cannabis Hemp Conference and Expo Published 22nd Jun 2017 | Updated 14th July 2020 Dear Dr. Russo, Thank you for your prompt responses to our communications and for your highly valued knowledge. Kind regards, Nicholas Hill The Hemp Club SOURCE, YOUTUBE: https://www.youtube.com/watch?v=xtphZejvGhkRead more
Tag Archives: cannabinoids
SOURCE: THE ICCI With specific reference to Parkinson’s Disease (please read to the end of this blog for the link to the full Review). About: An undeniable global interest in the study of cannabis treatments inspired the creation of the International Cannabis and Cannabinoid Institute (ICCI), the first Center of Excellence in this field located in the heart of EuropeRead more
UK Government Letter of Guidance On Cannabis Based Products for Medicinal Use 31/10/18. Prior to legalization on 1st November 2018
A fantastic podcast on the topicRead more
SOURCE: https://www.newcannabisventures.com/dea-green-lights-epidiolex-as-first-cannabis- September 27, 2018 at 9:22 am Breaking News by Alan Brochstein, CFA The DEA has given Epidiolex, the CBD-based pharmaceutical derived from cannabis that was approved by the FDA for the treatment of rare forms of epilepsy in June, Schedule V status according to the Office of the Federal Register. The developer of the pharmaceutical, GW Pharma (NASDAQ:Read more
Detailed analysis of selected pathological conditions and effects of cannabis and its derivatives with weaker clinical evidence and a strong theoretical basis favoring effectiveness. With reference to Parkinson’s disease.
A short quote from the .pdf (a link to the detailed analysis is at the end of this post). ” Parkinson’s disease This disease, whose symptoms especially include a decrease in the number of dopaminergic neurons in the basal ganglia (“BG”), is, due to its high prevalence (especially among older patients) and simultaneous existence of endocannabinoid receptors in the BGRead more